An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression

An International, Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00128505

Enrollment

104

Registered

2005-08-10

Start date

2005-08-31

Completion date

2006-11-30

Last updated

2012-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder, Psychotic Disorders

Keywords

PMD, Depression, Psychosis, Psychotic Major Depression, Major Depression

Brief summary

Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. If Corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. The purpose of this study is to allow patients who have already participated in an earlier 8 week study of Corlux versus placebo (an inactive pill) to receive additional courses of treatment with Corlux periodically if a psychotic episode should reappear during a period of one year.

Interventions

DRUGMifepristone

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Completed participation through Day 56 in Corcept Therapeutics Protocol C-1073-09 * Are 18 to 75 years of age * Have a diagnosis of major depressive disorder with psychotic features (DSM-IV 296.24 or 296.34) * Are able to provide written informed consent

Exclusion criteria

* Have a major medical problem * Have a history of an allergic reaction to CORLUX (C-1073, mifepristone)

Design outcomes

Primary

Measure	Time frame
To evaluate the safety and tolerability of Corlux (mifepristone) for the treatment of recurrent psychotic symptoms with major depression with psychotic features (PMD) who previously participated in Corcept Therapeutics Protocol C-1073-09	—

Secondary

Measure	Time frame
To assess the frequency of retreatment with Corlux in patients with PMD and qualitatively describe the psychotic symptoms for which retreatment is clinically indicated	—

Countries

Bulgaria, Croatia, Romania, Serbia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026